Weil, Gotshal and Manges has lost its corporate chair, Michael Aiello, widely regarded inside the firm as its single most powerful partner and standout rainmaker. Despite Aiello’s status as the firm’s biggest
Coats Group (COA) climbed to the top of the FTSE 250 leaderboard after the thread and yarn manufacturer reported resilient first-half financial results. The London-listed industrial group, which supplies thread and structural
More
GSK has unveiled a sweeping three-year cost-savings programme worth £1.9 billion, equivalent to around $2.5 billion, aimed at reshaping how the British drugmaker allocates its resources. The plan, announced by chief executive
More
The Securities and Exchange Commission proposed Regulation E-Delivery on July 16, 2026, marking a significant shift in how investment advisers may fulfil their disclosure obligations. The proposal would allow investment advisers to
More
The FTSE 100 index is on course to end 2026 with gains of around 9%, marking what would be its sixth consecutive year of positive returns. That performance, while solid, is being
More
The FTSE 250 index saw a cluster of notable movers push higher, with Coats, Man Group, and SSP Group among the standout performers during the session. Coats Group, the industrial thread and
More
Johnson & Johnson (JNJ) has proposed a $5.5 billion settlement to resolve approximately 76,000 ovarian cancer lawsuits filed at both the multi-district litigation and state levels. Law firms representing 99.75% of plaintiffs
More
Businesses banking on recent federal court decisions to expand their SMS marketing campaigns may be walking into a legal minefield at the state level. While the Stendingr decision and certain district court
More
Glencore (GLEN.L) has accused Winston Soosaipillai, the former owner of collapsed Lincolnshire oil refinery Prax, of orchestrating a $236m (£177m) fraud against the FTSE 100 commodity giant. The Anglo-Swiss company claims Soosaipillai
More
Bloom Energy (NYSE: BE) delivered a stronger-than-expected second quarter in CY2026, sending its stock sharply higher as investors responded to the upbeat results. The San Jose-based fuel cell company has been closely
More
Jiangsu Hengrui Pharma and Elevar Therapeutics have seen their hopes for a first-line liver cancer combination approval dashed by two separate FDA citations. The FDA issued complete response letters targeting the combination
More